Millinette (Ethinylestradiol, Gestodene)

Ethinylestradiol provides estrogenic activity while gestodene supplies progestogenic activity. Together they suppress the hypothalamic‑pituitary‑ovarian axis, reducing LH and FSH release, which blocks follicular development and ovulation. The progestogen also thickens cervical mucus and alters the endometrium, preventing sperm penetration and implantation.

The dosing regimen for Millinette is determined by the prescribing healthcare professional. Typically, one tablet is taken daily at the same time, but the exact schedule, duration of a placebo week, and any adjustments are set by the prescriber based on individual needs.

Millinette is classified as pregnancy category X, meaning it must not be used during pregnancy because it can harm the fetus. While limited data exist for breastfeeding, the product is generally not recommended unless the benefits outweigh potential risks, and a clinician should be consulted.

To order Millinette, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Millinette contains a low‑dose estrogen (30 µg ethinylestradiol) combined with gestodene, a third‑generation progestogen. Compared with older formulations that use higher estrogen doses or different progestins, Millinette offers comparable contraceptive efficacy with a potentially lower risk of estrogen‑related side effects, while gestodene may have a slightly different bleeding profile.

Millinette tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Millinette is taken orally as a single tablet each day, preferably at the same time each day. It may be taken with or without food. A typical cycle includes 21 active tablets followed by a 7‑day placebo interval, but the exact regimen is defined by the prescriber.

The most serious risks include venous thromboembolism, arterial thrombosis such as stroke or myocardial infarction, and severe hypertension. These events are rare but can be life‑threatening, especially in women with pre‑existing risk factors like smoking, obesity, or a history of clotting disorders.

Millinette is contraindicated in pregnant or breastfeeding women, smokers over 35 years, individuals with a history of thromboembolic disease, known or suspected hormone‑dependent cancers, severe liver disease, uncontrolled hypertension, or any condition where combined estrogen‑progestogen therapy is unsafe.